The data suggest that specific targeting of cyclin B1 could sensitize some gynecological cancer cells, like MCF-7 and MDA-MB-231 cells, to conventional chemotherapeutic agents like taxol, thereby reducing their side-effects by lowering their dosage. Here, CCNB1 is linked to female reproductive organ cancer.